GENMAB Buy scenarioI am loking to get into a buy at best after the downward trendline is broken and the SMA(89) is crossed to the upside afterwards.
See examples in the past as indicated by my green circles...
Leave a like or comment, please
GMAB trade ideas
Watch out for long position in GenmabGenmab has reached an important area, which before in time have been a good time to start a long postion.
Genmap Correction -40 %I like Genmab. The stock was one of my long positions for many years. I went into cash in the fall of 2021. After minus 40 percent, I will now gradually add to Genmab again.
Genmab is a era done ?I have sold all of my genmab shares i started to buy at the start of corona, 5 year tmeframe i think we see a head an shoulder formation an hoping to buy again 15-1600 kr :)
in the stockHello again, i bought this stock last year at like 1500 kr, but unf. i see a Head an should forming in think it will fall a little back, of course i hope im wrong an go up from here :) An not selling holding at least 5-20 years :)
Inverse Cup and handle on the weekly $GMABInverse Cup and handle on the weekly $GMAB
- Inverse Cup and handle on the weekly
- VPVR acting as resistance
- Waiting for a trigger
Interesting cup with handle developmentLooks like we have a cup with handle. Potential target 3600-3800
Genmab opportunitysteamloss in the Genmab stock will likely fuel a new rush.
1) the 2 previous times times RSI has been below 30, it has resulted in strong returns. Will it happen a 3rd time?
2) The current strongly rising RSI will like make sure that the price will move and stay above the short term downward trend.
3) Opportunity for the price to move towards 2557 DKK. Yet be aware of potential strong resistance around 2364 DKK.
4) If this small up trend can offset the short term setback, 50/200 will likely trigger a new golden cross.
Entered long in 2168 DKK
GMAB - Potential Long Term Growth ProspectSome basic chart analysis on Genmab.
This is more to bring your attention to the stocks long term growth prospects.
With a TTM P/E ratio of 29 and a FWD of 3, combined with solid revenue growth TTM and FWD leads me to suggest that Genmab will thrive in the coming months and climb to all time highs.
GENMAB A/SGENMAB A/S
Our contribution has known a strong acceleration and impressive upward defense positive and still He is on a strong track and the prospect of purchase is still A fresh list of buyers' abundance and strong size
GMAB Bull flagI've been reading through their studies to see what they're working on and what their proprietary info is being used for and it's actually impressive. Best part is that several of these studies are big on the public conscience, when one of these pops, I can easily see interest in this company peaking real quick.
Partnerships with several major companies: BNTX, AMGN, JNJ, BMY.
Note: BNTX is an absolutely incredible company, the stuff they're working out have potential to revolutionize medicine. Not overexagerating.
FA: Net income, employees, etc all up each quarter.
13D: 3% held by major hedge funds.
Analyst: Overweight by MS w/ PT upgrade to 41
TA: Bull flag. PT = 43$ at least.
Genmab $GMAB all time high after Q3 earnings beat #biotechNovember 4, 2020; Copenhagen, Denmark;
Interim Report for the First Nine Months Ended September 30, 2020
Highlights
Novartis granted U.S. FDA approval for Kesimpta® (ofatumumab) in relapsing multiple sclerosis
Janssen and European Myeloma Network achieved positive topline results from Phase 3 APOLLO study of daratumumab in relapsed or refractory multiple myeloma
Janssen was granted U.S. FDA approval for DARZALEX® (daratumumab) in combination with carfilzomib and dexamethasone in relapsed or refractory multiple myeloma based on Phase 3 CANDOR study
DARZALEX net sales increased 35% compared to the first nine months of 2019 to USD 2,937 million, resulting in royalty income of DKK 2,898 million for the first nine months of 2020
Genmab (GNMSF) commenced binding arbitration of two matters under daratumumab license agreement with Janssen
Announcement of plan to transition Arzerra® (ofatumumab) to an oncology access program for chronic lymphocytic leukemia patients in the U.S.
“Genmab continued to deliver on the promise of improving the lives of patients, with multiple regulatory milestones for Genmab-created products under development by our partners, including the exciting U.S. FDA’s approval of Kesimpta and the 8th U.S. FDA approval for DARZALEX,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. “During the first nine months of 2020, with our solid financial footing Genmab has continued its focused investment in advancing its proprietary antibody product pipeline and building its capabilities as we evolve into a fully integrated biotech.”
Financial Performance First Nine Months of 2020
Revenue was DKK 8,067 million in the first nine months of 2020 compared to DKK 2,405 million in the first nine months of 2019. The increase of DKK 5,662 million, or 235%, was primarily driven by the upfront payment from AbbVie pursuant to our new collaboration announced in June and higher DARZALEX royalties.
Net sales of DARZALEX by Janssen Biotech Inc. (Janssen) were USD 2,937 million in the first nine months of 2020 compared to USD 2,168 million in the first nine months of 2019, an increase of USD 769 million, or 35%.
Operating expenses were DKK 2,641 million in the first nine months of 2020 compared to DKK 1,943 million in the first nine months of 2019. The increase of DKK 698 million, or 36%, was driven by the advancement of epcoritamab (DuoBody®-CD3xCD20) and DuoBody-PD-L1x4-1BB, additional investments in our product pipeline, and the increase in new employees to support the expansion of our product pipeline.
Operating income was DKK 5,426 million in the first nine months of 2020 compared to DKK 462 million in the first nine months of 2019. The increase of DKK 4,964 million was driven by higher revenue, which was partly offset by increased operating expenses.
Outlook
Genmab is maintaining its 2020 financial guidance published on August 20, 2020.
Genmab - 2000 DKK must holdAfter the royalty issue with Janssen announced today we have seen a sudden decrease. I would say 2000 DKK is a buying zone/support level and it must be held if the stock price should rise to new ATH again.
Genmab AS (GMAB - NASDAQ) - Bulls holding tightGenmab AS (GMAB - NASDAQ) is in 4th subwave of 5th wave up, wait for one leg down to complete 4th subwave to get in to trade, from where it again resumes the up cycle. The invalidation level for 33.52, the high of 1st subwave.
I recommend buying again GMAB will continue to climb in the coming days
Because we are above the blue line and we have a green candle that corresponds to raising the volume
Will the trend hold?Back in late 2014 Genmab broke out and haven't looked back since, though it have seen many downturns on the way, as we can see it has been through 4 big downturns of 25%+ drops. Another one could be in motion, a weekly bearish engulfing candle has formed and we have seen it drop 15% and is now back testing the former resistance and is about to test the bottom support trendline . If it doesn't hold we could likely see another 15% drop back to 1228 kr .
